The TRUPCR® MGMT Methylation Detection Kit is specifically designed to assess the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. This crucial biomarker plays a pivotal role in predicting the response of glioblastoma patients to alkylating agents like temozolomide (TMZ).
Understanding MGMT Methylation PCR
MGMT plays a crucial role in DNA repair mechanisms, specifically repairing alkylated DNA lesions induced by chemotherapy agents like temozolomide (TMZ). Methylation of the MGMT promoter region silences its expression, thereby impairing this repair mechanism. Patients with glioblastoma who exhibit MGMT promoter methylation are more likely to respond favorably to TMZ treatment, making the accurate assessment of methylation status essential for personalized treatment decisions.
Solution by TRUPCR®
The TRUPCR® MGMT Methylation Detection Kit utilizes Methylation-specific real-time polymerase chain reaction (qMSPCR). This technology enables the selective amplification of methylated and unmethylated alleles within the MGMT promoter region after DNA undergoes bisulfite treatment. Bisulfite treatment converts unmethylated cytosines to uracils while leaving methylated cytosines unchanged, thereby distinguishing between methylated and unmethylated DNA sequences.
The workflow of the TRUPCR® MGMT Methylation Detection Kit begins with the bisulfite treatment of DNA samples, followed by amplification of target MGMT promoter regions using fluorescent probes labeled with FAM (for methylated) and HEX (for unmethylated alleles). This dual-probe system ensures accurate discrimination between methylated and unmethylated DNA sequences. Importantly, the kit includes an endogenous internal control to validate the quality of bisulfite-treated DNA, reducing the likelihood of false-negative results.
Key Features:
-
- First Commercial Real-time PCR Assay: The first commercially available assay for real-time PCR detection of MGMT promoter methylation, the kit sets a new standard in precision medicine.
- Selective Amplification: Ensures specific amplification of both methylated and unmethylated alleles, providing comprehensive insights into the methylation status critical for treatment decisions.
- Endogenous Internal Control: Includes an internal control to validate bisulfite-treated DNA quality, ensuring reliable and reproducible results.
- Compatibility: Designed for seamless integration with various real-time PCR instruments, enhancing versatility and accessibility in laboratory settings.
- High Sensitivity and Specificity: Offers enhanced sensitivity and specificity, coupled with a streamlined workflow for rapid and reliable analysis.
- Cost-effectiveness: Provides a cost-effective solution without compromising on the depth and accuracy of methylation status assessment.
Ordering Information:
| CAT. NO. | PRODUCT | CONTENTS |
|---|---|---|
| 3B1339 | TRUPCR® MGMT Methylation Detection Kit | 24 Reactions |
| 3B1340 | TRUPCR® MGMT Methylation Detection Kit | 48 Reactions |
The ability to accurately determine MGMT promoter methylation status is pivotal in clinical practice, particularly in oncology. Patients with glioblastoma who exhibit MGMT promoter methylation typically have a better response to alkylating agent therapy, such as TMZ, compared to those without methylation. This diagnostic clarity aids oncologists in tailoring treatment plans to maximize therapeutic efficacy and patient outcomes.
TRUPCR® MGMT Methylation Detection Kit is specifically designed to empower clinicians with accurate and timely information regarding MGMT promoter methylation status. By leveraging state-of-the-art qMSPCR technology, the kit ensures robust performance, high sensitivity, and reliable results essential for personalized treatment strategies in glioblastoma management.
